Skip to Main ContentSkip to FooterSkip to Search
  1. Home
  2.  » 
  3. Catalent News
  4.  » Strategies To Improve Clinical Supply Execution Through Integrated Development And Partnering To Be Discussed By Catalent
Wifi Icon

Strategies To Improve Clinical Supply Execution Through Integrated Development And Partnering To Be Discussed By Catalent

Catalent Experts to Present at CTS Europe and CTS New England

SOMERSET, N.J. – March 5, 2019 — Catalent Pharma Solutions, a global leader in clinical supply services, today announced that three of its experts will present at two upcoming conferences, Clinical Trial Supply (CTS) Europe and CTS New England.

Iain Webb, Account Executive and CRO Specialist, Clinical Supply Services, will present at the 20th annual CTS Europe conference, to be held at the NH Milano Congress Center, Milan, Italy on March 13-14, 2019. Mr. Webb’s presentation, “The Clinical Supply Conversation That Every Sponsor Needs to Have with Their CRO”, on Thursday, March 14 at 10:30 a.m., will explore the aspects of clinical supply that present the greatest challenges to both sponsors and contract research organizations (CROs). Mr. Webb will discuss how to establish a practical and sustainable communication strategy with a CRO, explain how protocol design can impact clinical supply strategy, and outline strategies to address potential challenges.

Lisa Caralli, Director, Science and Technology and Ann McMahon, Customer Service Excellence Manager, will present at the 8th annual CTS New England conference, to be held at The Westin Boston Waterfront Hotel, Boston, on March 26-27, 2019. Their presentation, on Tuesday, March 26 at 11:15 a.m., entitled, “Next Exit, Success: Get from Concept to Clinic Faster on the Product Development Superhighway”, will explore the benefits of contracting with a single integrated provider. Ms. Caralli and Ms. McMahon will explain how to identify opportunities to streamline product development, shorten timelines, and reduce the risk of avoidable delays. Their presentation will also explore how dosage form selection can shape future decisions and a project’s trajectory.

Mr. Webb has over 10 years of industry experience, and in his role, supports CRO customers and their sponsors with the full range of Catalent’s clinical supply services. Mr. Webb previously worked within Catalent’s global Client Services team working with a range of CROs and sponsors, from small and virtual companies to large multinational corporations. He holds a bachelor’s degree in biology from Manchester Metropolitan University, Manchester, U.K.

Ms. Caralli has over 27 years of industry experience, and in her role, works with pharmaceutical companies to identify the correct development pathway for their early development drug candidates. She previously held roles at Ionis Pharmaceuticals and Amylin Pharmaceuticals and began her career at the Immune Response Corporation and holds a bachelor’s degree in biochemistry from the University of California at Davis, Davis, California.

Ms. McMahon has over 17 years of experience in the pharmaceutical industry. Prior to joining Catalent, she was Manager, New Product Launch at West-Ward Pharmaceuticals and Boehringer Ingelheim. She holds a bachelor’s degree in biology/biochemistry from Ohio Northern University, Ada, Ohio and a master’s degree in clinical pharmacology from the Ohio State University, Columbus, Ohio.

To arrange a meeting with any of the Catalent executives attending either conference, contact Ed Dutton at NEPR –  

Media Contacts:

Chris Halling
+44 (0)7580 041073

Richard Kerns
+44 (0) 161 728 5880


Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit


More products. Better treatments. Reliably supplied.™